TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Reducing Clinical Inertia in Diabetes Care
Brief Summary: In this randomized trial we evaluate two conceptually distinct but potentially synergistic interventions designed to reduce clinical inertia in the outpatient care of adults with type 2 diabetes. The project addresses the following specific aims;

Specific Aim 1. Implement and assess two conceptually distinct but potentially synergistic interventions to reduce clinical inertia related to control of A1c, SBP, and LDL in adults with diabetes.

* Hypothesis 1. Patients of physicians who receive the Cognitive Behavioral Intervention (CBI) (Group 1) will subsequently have less Clinical Inertia than those who receive no intervention (Group 4).
* Hypothesis 2. Patients of physicians who receive the Office Systems Redesign intervention (CBI) (Group 2) will subsequently have less Clinical Inertia than those who receive no intervention (Group 4).
* Hypothesis 3. Patients of physicians who receive the combined CBI plus OSR intervention (Group 3) will subsequently have less Clinical Inertia than those who receive CBI alone (Group 1) or OSR alone (Group 2).

Specific Aim 2. Assess the impact of interventions to reduce clinical inertia on health care charges.

• Hypothesis 4. After adjustment for baseline measures of health care charges, those who receive no intervention (Group 4), will have higher total health care charges over a 24-month follow-up, relative to the patients of physicians in intervention Group 1, Group 2, or Group 3.


Options:
A: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Other: Mobile Health Care Environment (MHCE) | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Mobile Health Care Environment (MHCE); Assigned to Arm(s): Intervention
B: Intervention Type: BEHAVIORAL; Name: Nurse Case Manager and Community Health Worker Team; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: OTHER; Interventions: Behavioral: Cognitive Behavioral Intervention | Arm Label: 2; Type: OTHER; Interventions: Behavioral: Office System Redesign Intervention | Arm Label: 3; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Intervention; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Office System Redesign Intervention; Assigned to Arm(s): 2
D: Intervention Type: BEHAVIORAL; Name: Customized Physician Intervention; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Customized Patient Intervention; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Reducing Clinical Inertia in Diabetes Care
Brief Summary: In this randomized trial we evaluate two conceptually distinct but potentially synergistic interventions designed to reduce clinical inertia in the outpatient care of adults with type 2 diabetes. The project addresses the following specific aims;

Specific Aim 1. Implement and assess two conceptually distinct but potentially synergistic interventions to reduce clinical inertia related to control of A1c, SBP, and LDL in adults with diabetes.

* Hypothesis 1. Patients of physicians who receive the Cognitive Behavioral Intervention (CBI) (Group 1) will subsequently have less Clinical Inertia than those who receive no intervention (Group 4).
* Hypothesis 2. Patients of physicians who receive the Office Systems Redesign intervention (CBI) (Group 2) will subsequently have less Clinical Inertia than those who receive no intervention (Group 4).
* Hypothesis 3. Patients of physicians who receive the combined CBI plus OSR intervention (Group 3) will subsequently have less Clinical Inertia than those who receive CBI alone (Group 1) or OSR alone (Group 2).

Specific Aim 2. Assess the impact of interventions to reduce clinical inertia on health care charges.

• Hypothesis 4. After adjustment for baseline measures of health care charges, those who receive no intervention (Group 4), will have higher total health care charges over a 24-month follow-up, relative to the patients of physicians in intervention Group 1, Group 2, or Group 3.


Options:
A: Arm Label: Rating and Ranking Group; Type: OTHER; Interventions: Other: Rating and Ranking Task | Arm Label: Discrete Choice Group; Type: OTHER; Interventions: Other: Discrete Choice Task | Arm Label: Balance Sheet Group; Type: OTHER; Interventions: Other: Balance Sheet Task | Intervention Type: OTHER; Name: Rating and Ranking Task; Assigned to Arm(s): Rating and Ranking Group | Intervention Type: OTHER; Name: Discrete Choice Task; Assigned to Arm(s): Discrete Choice Group | Intervention Type: OTHER; Name: Balance Sheet Task; Assigned to Arm(s): Balance Sheet Group
B: Arm Label: 1; Type: OTHER; Interventions: Behavioral: Cognitive Behavioral Intervention | Arm Label: 2; Type: OTHER; Interventions: Behavioral: Office System Redesign Intervention | Arm Label: 3; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Intervention; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Office System Redesign Intervention; Assigned to Arm(s): 2
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Heart to Heart (Web-Based Decision Aid), Behavioral: Physician Education Session | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Heart to Heart (Web-Based Decision Aid); Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Physician Education Session; Assigned to Arm(s): 1
D: Intervention Type: BEHAVIORAL; Name: Academic Detailing (Medical Practices)+Decision Aids (Patients); Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The SU.VI.MAX Study. A Randomized, Placebo-controlled Prevention Trial of the Health Effects of Antioxidant Vitamins and Minerals.
Brief Summary: It has been suggested that a low dietary intake of antioxidant vitamins and minerals increases the incidence rate of cardiovascular disease and cancer. To date, however, the published results of randomized, placebo-controlled trials of supplements containing antioxidant nutrients have not provided clear evidence of a beneficial effect. We tested the efficacy of nutritional doses of supplementation with a combination of antioxidant vitamins and minerals in reducing the incidence of cancer and ischemic cardiovascular disease in the general population.


Options:
A: Intervention Type: BEHAVIORAL; Name: ascorbic acid, vitamin E, beta carotene, selenium, zinc; Assigned to Arm(s): N/A
B: Intervention Type: BEHAVIORAL; Name: folic acid (0.8 mg); Assigned to Arm(s): N/A
C: Arm Label: Vitamin E; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin E | Arm Label: Vitamin C; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin C | Arm Label: Multivitamin; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Multivitamin | Arm Label: Beta-carotene; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Beta-carotene | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin E; Assigned to Arm(s): Vitamin E | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin C; Assigned to Arm(s): Vitamin C | Intervention Type: DIETARY_SUPPLEMENT; Name: Multivitamin; Assigned to Arm(s): Multivitamin | Intervention Type: DIETARY_SUPPLEMENT; Name: Beta-carotene; Assigned to Arm(s): Beta-carotene
D: Arm Label: vitamin supplements; Type: EXPERIMENTAL; Interventions: Drug: Folic Acid, Drug: Vitamin B6, Drug: Vitamin B12 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Folic Acid; Assigned to Arm(s): vitamin supplements | Intervention Type: DRUG; Name: Vitamin B6; Assigned to Arm(s): vitamin supplements | Intervention Type: DRUG; Name: Vitamin B12; Assigned to Arm(s): vitamin supplements | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The SU.VI.MAX Study. A Randomized, Placebo-controlled Prevention Trial of the Health Effects of Antioxidant Vitamins and Minerals.
Brief Summary: It has been suggested that a low dietary intake of antioxidant vitamins and minerals increases the incidence rate of cardiovascular disease and cancer. To date, however, the published results of randomized, placebo-controlled trials of supplements containing antioxidant nutrients have not provided clear evidence of a beneficial effect. We tested the efficacy of nutritional doses of supplementation with a combination of antioxidant vitamins and minerals in reducing the incidence of cancer and ischemic cardiovascular disease in the general population.


Options:
A: Intervention Type: BEHAVIORAL; Name: ascorbic acid, vitamin E, beta carotene, selenium, zinc; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Vitamin E, Vitamin C, and Alpha-lipoic Acid, Drug: Placebo wafers | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Coenzyme Q, Drug: Placebo capsules | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo capsules, Drug: Placebo wafers | Intervention Type: DRUG; Name: Vitamin E, Vitamin C, and Alpha-lipoic Acid; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Coenzyme Q; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo capsules; Assigned to Arm(s): 2, 3 | Intervention Type: DRUG; Name: Placebo wafers; Assigned to Arm(s): 1, 3
C: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Study Arm A | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Study Arm B | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Study Arm C | Arm Label: 4; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Study Arm D | Intervention Type: DIETARY_SUPPLEMENT; Name: Study Arm A; Assigned to Arm(s): 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: Study Arm B; Assigned to Arm(s): 2 | Intervention Type: DIETARY_SUPPLEMENT; Name: Study Arm C; Assigned to Arm(s): 3 | Intervention Type: DIETARY_SUPPLEMENT; Name: Study Arm D; Assigned to Arm(s): 4
D: Arm Label: Vitamin E; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin E | Arm Label: Vitamin C; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin C | Arm Label: Multivitamin; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Multivitamin | Arm Label: Beta-carotene; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Beta-carotene | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin E; Assigned to Arm(s): Vitamin E | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin C; Assigned to Arm(s): Vitamin C | Intervention Type: DIETARY_SUPPLEMENT; Name: Multivitamin; Assigned to Arm(s): Multivitamin | Intervention Type: DIETARY_SUPPLEMENT; Name: Beta-carotene; Assigned to Arm(s): Beta-carotene

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The SU.VI.MAX Study. A Randomized, Placebo-controlled Prevention Trial of the Health Effects of Antioxidant Vitamins and Minerals.
Brief Summary: It has been suggested that a low dietary intake of antioxidant vitamins and minerals increases the incidence rate of cardiovascular disease and cancer. To date, however, the published results of randomized, placebo-controlled trials of supplements containing antioxidant nutrients have not provided clear evidence of a beneficial effect. We tested the efficacy of nutritional doses of supplementation with a combination of antioxidant vitamins and minerals in reducing the incidence of cancer and ischemic cardiovascular disease in the general population.


Options:
A: Arm Label: vitamin supplements; Type: EXPERIMENTAL; Interventions: Drug: Folic Acid, Drug: Vitamin B6, Drug: Vitamin B12 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Folic Acid; Assigned to Arm(s): vitamin supplements | Intervention Type: DRUG; Name: Vitamin B6; Assigned to Arm(s): vitamin supplements | Intervention Type: DRUG; Name: Vitamin B12; Assigned to Arm(s): vitamin supplements | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
B: Intervention Type: BEHAVIORAL; Name: dietary supplements; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vitamin C; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vitamin E; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: beta-carotene; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: folic acid/Vitamin B6/Vitamin B12; Assigned to Arm(s): N/A
C: Intervention Type: BEHAVIORAL; Name: ascorbic acid, vitamin E, beta carotene, selenium, zinc; Assigned to Arm(s): N/A
D: Arm Label: Active VITATOPS Tablet (folic acid 2mg, B6 25mg , B12 500ug); Type: ACTIVE_COMPARATOR; Interventions: Drug: Active VITATOPS Tablet (folic acid 2mg, B6 25mg , B12 500ug) or placebo | Arm Label: Placebo Tablet; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Active VITATOPS Tablet (folic acid 2mg, B6 25mg , B12 500ug) or placebo; Assigned to Arm(s): Active VITATOPS Tablet (folic acid 2mg, B6 25mg , B12 500ug) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo Tablet

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The SU.VI.MAX Study. A Randomized, Placebo-controlled Prevention Trial of the Health Effects of Antioxidant Vitamins and Minerals.
Brief Summary: It has been suggested that a low dietary intake of antioxidant vitamins and minerals increases the incidence rate of cardiovascular disease and cancer. To date, however, the published results of randomized, placebo-controlled trials of supplements containing antioxidant nutrients have not provided clear evidence of a beneficial effect. We tested the efficacy of nutritional doses of supplementation with a combination of antioxidant vitamins and minerals in reducing the incidence of cancer and ischemic cardiovascular disease in the general population.


Options:
A: Intervention Type: BEHAVIORAL; Name: Four Diets Differing in Macronutrient Composition; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Diets Low in Saturated Fat; Assigned to Arm(s): N/A
B: Intervention Type: BEHAVIORAL; Name: ascorbic acid, vitamin E, beta carotene, selenium, zinc; Assigned to Arm(s): N/A
C: Arm Label: Synbiotic; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Synbiotic | Arm Label: Maltodextrin; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Maltodextrin | Intervention Type: DIETARY_SUPPLEMENT; Name: Synbiotic; Assigned to Arm(s): Synbiotic | Intervention Type: DIETARY_SUPPLEMENT; Name: Maltodextrin; Assigned to Arm(s): Maltodextrin
D: Arm Label: 1.; Type: EXPERIMENTAL; Interventions: Drug: DHA (Docosahexaenoic Acid) | Arm Label: 2.; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: DHA (Docosahexaenoic Acid); Assigned to Arm(s): 1. | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2.

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The SU.VI.MAX Study. A Randomized, Placebo-controlled Prevention Trial of the Health Effects of Antioxidant Vitamins and Minerals.
Brief Summary: It has been suggested that a low dietary intake of antioxidant vitamins and minerals increases the incidence rate of cardiovascular disease and cancer. To date, however, the published results of randomized, placebo-controlled trials of supplements containing antioxidant nutrients have not provided clear evidence of a beneficial effect. We tested the efficacy of nutritional doses of supplementation with a combination of antioxidant vitamins and minerals in reducing the incidence of cancer and ischemic cardiovascular disease in the general population.


Options:
A: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Study Arm A | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Study Arm B | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Study Arm C | Arm Label: 4; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Study Arm D | Intervention Type: DIETARY_SUPPLEMENT; Name: Study Arm A; Assigned to Arm(s): 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: Study Arm B; Assigned to Arm(s): 2 | Intervention Type: DIETARY_SUPPLEMENT; Name: Study Arm C; Assigned to Arm(s): 3 | Intervention Type: DIETARY_SUPPLEMENT; Name: Study Arm D; Assigned to Arm(s): 4
B: Arm Label: PGZ; Type: EXPERIMENTAL; Interventions: Drug: pioglitazone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: pioglitazone; Assigned to Arm(s): PGZ | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Vitamin E + selenium placebo; Type: EXPERIMENTAL; Interventions: Drug: Vitamin E, Other: selenium placebo | Arm Label: Selenium + vitamin E placebo; Type: EXPERIMENTAL; Interventions: Drug: Selenium, Other: Vitamin E placebo | Arm Label: Vitamin E + selenium; Type: EXPERIMENTAL; Interventions: Drug: Vitamin E, Drug: Selenium | Arm Label: Vitamin E placebo + selenium placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Vitamin E placebo, Other: selenium placebo | Intervention Type: DRUG; Name: Vitamin E; Assigned to Arm(s): Vitamin E + selenium, Vitamin E + selenium placebo | Intervention Type: DRUG; Name: Selenium; Assigned to Arm(s): Selenium + vitamin E placebo, Vitamin E + selenium | Intervention Type: OTHER; Name: Vitamin E placebo; Assigned to Arm(s): Selenium + vitamin E placebo, Vitamin E placebo + selenium placebo | Intervention Type: OTHER; Name: selenium placebo; Assigned to Arm(s): Vitamin E + selenium placebo, Vitamin E placebo + selenium placebo
D: Intervention Type: BEHAVIORAL; Name: ascorbic acid, vitamin E, beta carotene, selenium, zinc; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The SU.VI.MAX Study. A Randomized, Placebo-controlled Prevention Trial of the Health Effects of Antioxidant Vitamins and Minerals.
Brief Summary: It has been suggested that a low dietary intake of antioxidant vitamins and minerals increases the incidence rate of cardiovascular disease and cancer. To date, however, the published results of randomized, placebo-controlled trials of supplements containing antioxidant nutrients have not provided clear evidence of a beneficial effect. We tested the efficacy of nutritional doses of supplementation with a combination of antioxidant vitamins and minerals in reducing the incidence of cancer and ischemic cardiovascular disease in the general population.


Options:
A: Intervention Type: BEHAVIORAL; Name: ascorbic acid, vitamin E, beta carotene, selenium, zinc; Assigned to Arm(s): N/A
B: Arm Label: N-3 PUFA; Type: EXPERIMENTAL; Interventions: Drug: N-3 Polyunsaturated Fatty Acids | Arm Label: Olive oil; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo: Olive oil | Intervention Type: DRUG; Name: N-3 Polyunsaturated Fatty Acids; Assigned to Arm(s): N-3 PUFA | Intervention Type: DRUG; Name: Placebo: Olive oil; Assigned to Arm(s): Olive oil
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Arm Label: Flaxseed; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Flaxseed | Intervention Type: DIETARY_SUPPLEMENT; Name: Flaxseed; Assigned to Arm(s): Flaxseed | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Walnut group; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Walnuts | Arm Label: Control group; Type: ACTIVE_COMPARATOR; Interventions: Other: habitual diet | Intervention Type: DIETARY_SUPPLEMENT; Name: Walnuts; Assigned to Arm(s): Walnut group | Intervention Type: OTHER; Name: habitual diet; Assigned to Arm(s): Control group

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: To evaluate current and novel therapies and management strategies for children with asthma. The emphasis is on clinical trials that help identify optimal therapy for children with different asthma phenotypes, genotypes, and ethnic backgrounds and children at different developmental stages.


Options:
A: Arm Label: Reference Strategy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Inhaled corticosteroids | Arm Label: Biomarker Strategy; Type: EXPERIMENTAL; Interventions: Drug: Inhaled corticosteroids, Procedure: eNO measurement | Intervention Type: DRUG; Name: Inhaled corticosteroids; Assigned to Arm(s): Biomarker Strategy, Reference Strategy | Intervention Type: PROCEDURE; Name: eNO measurement; Assigned to Arm(s): Biomarker Strategy
B: Intervention Type: BEHAVIORAL; Name: Home-based adherence monitoring; Assigned to Arm(s): N/A
C: Arm Label: 1 Budesonide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Budesonide | Arm Label: 2 Nedocromil; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nedocromil | Arm Label: 3 Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3 Placebo | Intervention Type: DRUG; Name: Nedocromil; Assigned to Arm(s): 2 Nedocromil | Intervention Type: DRUG; Name: Budesonide; Assigned to Arm(s): 1 Budesonide
D: Intervention Type: DRUG; Name: inhaled corticosteroids; Assigned to Arm(s): N/A

Answer: D